<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078777</url>
  </required_header>
  <id_info>
    <org_study_id>108170</org_study_id>
    <nct_id>NCT03078777</nct_id>
  </id_info>
  <brief_title>The Effect Dialysis on the Pharmacokinetics of Fexofenadine</brief_title>
  <official_title>The Effect Dialysis on the Pharmacokinetics of Fexofenadine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators recently completed and published a study that demonstrated that&#xD;
      fexofenadine pharmacokinetics are significantly altered in dialysis patients (Thomson et al.&#xD;
      (2015) American Journal of Kidney Diseases 65(4):574-582). In this study, patients were&#xD;
      studied directly before routine dialysis treatment. Other published literature suggests the&#xD;
      timing of the dose of some drugs (before or after dialysis) may have a profound impact on the&#xD;
      drug pharmacokinetics (Nolin et al (2006) 17(9):2363-7). The hypothesis is that compounds&#xD;
      that accumulate in the blood of patients with kidney failure impact the pharmacokinetics such&#xD;
      that dosing before or after dialysis produces significantly different blood levels of the&#xD;
      drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open, randomized pharmacokinetic study in 30 patients treated by dialysis.&#xD;
      Patients will be asked to spend an additional 3 hours at the hospital on each of two study&#xD;
      days separated by at least a week. At the first study visit, the patient will be randomized&#xD;
      to receive the drug fexofenadine (120 mg, orally) either 3 hour prior to, OR at the&#xD;
      conclusion of their regularly scheduled dialysis treatment. Three hours following&#xD;
      fexofenadine administration, a single 4 mL (approximately 1 teaspoon) blood sample will be&#xD;
      drawn. One week or more after the first study day, the patient will have the study repeated&#xD;
      but with the timing of the dose altered to match the randomization. For example, if at the&#xD;
      first study visit the patient received fexofenadine after their dialysis session, they will&#xD;
      now receive the drug 3 hours prior to their dialysis session. The blood sample will be&#xD;
      centrifuged immediately and plasma stored at -80 celsius until analysis. Fexofenadine&#xD;
      concentration will be determine by liquid chromatography coupled to mass spectrometry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">November 29, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Fexofenadine Concentration</measure>
    <time_frame>3 hours following dosing</time_frame>
    <description>Measurement of Plasma Fexofenadine Concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Pre-Dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Dialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
    <description>Fexofenadine will be administered to patients.</description>
    <arm_group_label>Post-Dialysis</arm_group_label>
    <arm_group_label>Pre-Dialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients treated by any dialysis modality (e.g. hemodialysis, peritoneal dialysis) for&#xD;
             at least 90 days prior to study enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recent (within two weeks) hepatic or gastrointestinal morbidity. Inability&#xD;
             or refusal to provide written informed consent. Unable to provide a blood sample.&#xD;
             Female patients that are pregnant will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Urquhart, PhD</last_name>
      <phone>5196613756</phone>
      <email>Brad.Urquhart@schulich.uwo.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>March 7, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>November 23, 2017</last_update_submitted>
  <last_update_submitted_qc>November 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fexofenadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

